Saturday, October 31, 2026

Less Than One Hour Before The NASDAQ Open, MarketAxess Holdings Is Up By 5%

Less Than One Hour Before The NASDAQ Open, MarketAxess Holdings Is Up By 5%

(VIANEWS) - The NASDAQ opens in less than one hour and MarketAxess Holdings's pre-market value is already 5% up.

MarketAxess Holdings's last close was $214.52, 46.34% below its 52-week high of $399.78.

The last session, NASDAQ finished with MarketAxess Holdings (MKTX) sliding 2.32% to $214.52. NASDAQ fell 0.42% to $16,315.70, after two successive sessions in a row of losses, on what was a somewhat bearish trend exchanging session.

About MarketAxess Holdings

MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. The company offers trading technology that provides liquidity access in U.S. high-grade bonds, U.S. high-yield bonds, emerging market debt, eurobonds, municipal bonds, U.S. government bonds, and other fixed-income securities; and executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds through its Open Trading protocols. It also provides trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company offers various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, MarketAxess Holdings has a trailing twelve months EPS of $6.85.

PE Ratio

MarketAxess Holdings has a trailing twelve months price to earnings ratio of 31.32. Meaning, the purchaser of the share is investing $31.32 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.74%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Feb 13, 2024, the estimated forward annual dividend rate is 2.96 and the estimated forward annual dividend yield is 1.38%.

Growth Estimates Quarters

The company's growth estimates for the ongoing quarter is a negative 6.6% and positive 11.9% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.9%, now sitting on 752.55M for the twelve trailing months.

Moving Average

MarketAxess Holdings's value is way under its 50-day moving average of $244.37 and way under its 200-day moving average of $245.84.

More news about MarketAxess Holdings (MKTX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com